HAYMAN-1: Hayman's Haemostatic Suture to Treat Severe Post-partum Haemorrhage

Sponsor
Università degli Studi dell'Insubria (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03442491
Collaborator
(none)
90
20

Study Details

Study Description

Brief Summary

Post-partum haemorrhage continues to be a leading cause of maternal mortality and morbidity, accounting for more than 125 000 deaths per year across the world. Prompt diagnosis and effective action are the cornerstones of management and are crucial to prevent fatal maternal haemorrhage.

Considering that published data are extremely limited, the aim of our study will be to evaluate retrospectively the efficacy of Hayman's Haemostatic Suture for the treatment of resistant post-partum hemorrhage resistant to pharmacological therapy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Hayman's Haemostatic Suture

Detailed Description

Post-partum haemorrhage continues to be a leading cause of maternal mortality and morbidity, accounting for more than 125 000 deaths per year across the world. Prompt diagnosis and effective action are the cornerstones of management and are crucial to prevent fatal maternal haemorrhage.

The Hayman suture offers the potential advantages that can be applied fast and easy, a key point in an emergency situation, and avoids having to perform a lower segment hysterotomy when post-partum haemorrhage follows a vaginal delivery, therefore minimising the trauma to the atonic bleeding uterus.

Considering that published data are extremely limited, the aim of our study will be to evaluate retrospectively the efficacy of Hayman's Haemostatic Suture for the treatment of resistant post-partum hemorrhage resistant to pharmacological therapy.

Study Design

Study Type:
Observational
Anticipated Enrollment :
90 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Efficacy of Hayman's Haemostatic Suture for the Treatment of Severe Post-partum Haemorrhage Resistant to Pharmacologic Therapy
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2023
Anticipated Study Completion Date :
Feb 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Hayman's Haemostatic Suture

Women that had major Post-partum Haemorrhage, defined as postpartum blood loss in excess of 2000 ml, resistant to pharmacologic treatment and that underwent Hayman's Haemostatic Suture.

Procedure: Hayman's Haemostatic Suture
After the uterus is exteriorised, bimanual compression is applied to check whether this stopped the bleeding, before the suture is applied. A number 2 polyglactin suture on a straight needle is used to transfix the uterus from front to back, just above the reflection of the bladder, and is then tied above the fundus of the uterus, while an assistant applies bimanual compression.

Outcome Measures

Primary Outcome Measures

  1. Fertility preservation [Within 24 hours after post-partum haemorrhage]

    Number of cases in which it was not necessary to perform hysterectomy.

Secondary Outcome Measures

  1. Blood transfusions [Within 24 hours after post-partum haemorrhage]

    Intraoperative transfusions (units).

  2. Subsequent pregnancies [120 months from the date of post-partum haemorrhage.]

    Number of subsequent pregnancies (in case of successful management of Post-partum Haemorrhage)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women that had major Post-partum Haemorrhage, resistant to pharmacologic therapy, treated with Hayman's Haemostatic Suture.
Exclusion Criteria:
  • None.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Università degli Studi dell'Insubria

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Antonio Simone Laganà, Medical Doctor, Università degli Studi dell'Insubria
ClinicalTrials.gov Identifier:
NCT03442491
Other Study ID Numbers:
  • HAYMAN-1
First Posted:
Feb 22, 2018
Last Update Posted:
Sep 30, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Antonio Simone Laganà, Medical Doctor, Università degli Studi dell'Insubria
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 30, 2021